FDA


  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi gains FDA clearance for Gaucher disease pill

    The approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.

    By • Nov. 19, 2026
  • A photo of the exterior of Regeneron.
    Image attribution tooltip
    Permission granted by Regeneron
    Image attribution tooltip

    With FDA nod, Regeneron brings an RNAi drug to autoimmune disease

    The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx. 

    By • Nov. 19, 2026
  • FDA Commissioner nominee Heidi Overton testifies before Senate committee.
    Image attribution tooltip
    Tasos Katopodis via Getty Images
    Image attribution tooltip
    Trump administration

    White House pulls nomination for FDA nominee Overton

    The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say. 

    By • Nov. 18, 2026
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip

    Roche breast cancer pill cleared by FDA

    Wilserdly’s U.S. approval is seen by analysts as a “key first step” in an important launch for Roche, which has claimed the drug could become its top-selling product.

    By • Updated Nov. 17, 2026
  • Illustration of lung cancer
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Summit shares fall as FDA rejects closely watched PD-1/VEGF drug

    The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval. 

    By • Nov. 16, 2026
  • An illustration of vacancies for job openings.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trump administration

    The FDA has over 1k open jobs — and the staffing shortage is hitting pharma

    The agency is still recovering from a mass staff exodus last year that left it shorthanded. Here’s what it means for the industry.

    By Kelly Bilodeau • Nov. 12, 2026
  • Bayer
    Image attribution tooltip
    Permission granted by Bayer
    Image attribution tooltip

    Bayer wins FDA nod for a new kind of blood thinner

    Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention. 

    By • Nov. 9, 2026
  • A 3D illustration of a DNA double helix
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis reveals cancer cases possibly linked to gene therapy Zolgensma

    The FDA is now investigating the risk of malignancy associated with Zolgensma and is “evaluating whether regulatory action is appropriate.”

    By • Updated Nov. 9, 2026
  • U.S. Health and Human Services Secretary Robert F. Kennedy Jr. testifies during a hearing of the House Education And Workforce Committee on Capitol Hill on April 17, 2026 in Washington, DC.
    Image attribution tooltip
    Heather Diehl/Getty Images via Getty Images
    Image attribution tooltip
    Trump administration

    HHS to allow compounders to make 6 unapproved peptides

    RFK Jr. has given notice that the agency won’t take enforcement action on six peptides that controversially won a contested recommendation from outside advisers to the FDA in July.

    By Kristin Jensen • Oct. 29, 2026
  • A picture of FDA commissioner Kyle Diamantas speaking at an event in Washington DC.
    Image attribution tooltip
    Win McNamee / Staff via Getty Images
    Image attribution tooltip
    Gene editing

    FDA unveils guidance for ‘plug and play’ gene therapies

    The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies benefiting different subsets of patients with the same disease.

    By Kristin Jensen • Oct. 28, 2026
  • A photo of Biohaven CEO Vlad Coric
    Image attribution tooltip
    Courtesy of Biohaven Ltd.
    Image attribution tooltip

    Biohaven’s previously rejected rare disease drug to get fresh FDA review

    U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease medicine spurned by previous FDA leadership.

    By • Oct. 22, 2026
  • A modern architectural design building featuring a red-brick façade with large glass windows displays a prominent sign of the Food and Drug Administration.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    GSK, Ionis win US approval for first-of-its-kind hepatitis B drug

    Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s goal of reaching £40 billion in annual revenue by 2031.

    By • Oct. 21, 2026
  • A magnifying glass enlarges the U.S. Food and Drug Administration website on a computer screen.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trump administration

    FDA ‘reset’ continues with new plan for reviewing rare disease drugs

    A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.

    By Kristin Jensen • Oct. 15, 2026
  • A 3D illustration of a pair of lungs inside the rib cage.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Bristol Myers dips on ‘confounding’ lung drug results

    Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.

    By • Oct. 12, 2026
  • A person in a blue pinstripe suit looks straight ahead.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    HHS launches new plan to strengthen vaccine injury research, reporting

    Spearheaded by vaccine skeptic Robert F. Kennedy Jr., the initiative will involve a new NIH clinic, an updated monitoring system and reimbursements for doctors who report suspected side effects.

    By • Updated Oct. 9, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Lilly, Foghorn part ways; Wave’s FDA-approved plans

    The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.

    By • Oct. 1, 2026
  • A modern architectural design building featuring a red-brick façade with large glass windows displays a prominent sign of the Food and Drug Administration.
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Trump administration

    5 FDA decisions to watch in the fourth quarter of 2026

    The next three months will feature anticipated decisions on a new kind of cancer immunotherapy, as well as medicines important to the futures of Roche, GSK and Gilead.

    By BioPharma Dive staff • Oct. 1, 2026
  • The exterior of the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA starts review of Roche’s multiple sclerosis pill

    The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.

    By • Sept. 30, 2026
  • eye
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Kodiak skyrockets on positive study data for 2 eye drugs

    The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.

    By • Sept. 28, 2026
  • Merck sign
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck, Daiichi end plans to seek speedy approval of lung cancer ADC

    The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.

    By • Sept. 28, 2026
  • A hand in a blue glove holds a blood sample.
    Image attribution tooltip
    Courtesy of Grail
    Image attribution tooltip

    Grail multicancer detection test wins FDA advisers’ backing

    Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings, however.

    By Susan Kelly • Sept. 24, 2026
  • FDA Commissioner nominee Heidi Overton testifies before Senate committee.
    Image attribution tooltip
    Tasos Katopodis via Getty Images
    Image attribution tooltip
    Trump administration

    FDA nominee Overton parries vaccine questions at Senate hearing

    Pressed by lawmakers on Thursday, Trump’s pick as the next FDA chief said she’d “follow the law” on key decisions and work to speed early drug research.

    By • Sept. 24, 2026
  • An illustration of the collapse of a stock price
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Xenon shares fall following depression trial pause

    The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.

    By • Sept. 18, 2026
  • FDA magnifying glass
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    FDA launches pilot program to speed up early US drug research

    First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers with research institutions to more quickly bring medicines into human testing. 

    By • Sept. 15, 2026
  • A photo of the packaging for the spinal muscular atrophy drug Isemblyd.
    Image attribution tooltip
    Courtesy of Scholar Rock
    Image attribution tooltip

    Scholar Rock SMA drug approved by FDA

    Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in clinical testing, helped improve motor function in people on standard therapies. 

    By • Sept. 14, 2026